Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 Shares

Cartesian Therapeutics, Inc. (NASDAQ:RNACGet Free Report) CTO Metin Kurtoglu sold 2,458 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $16.83, for a total transaction of $41,368.14. Following the completion of the sale, the chief technology officer now owns 62,258 shares in the company, valued at approximately $1,047,802.14. This trade represents a 3.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Metin Kurtoglu also recently made the following trade(s):

  • On Friday, January 3rd, Metin Kurtoglu sold 2,417 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.72, for a total value of $40,412.24.
  • On Thursday, November 21st, Metin Kurtoglu sold 32,789 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.67, for a total value of $546,592.63.
  • On Monday, November 18th, Metin Kurtoglu sold 34,400 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $18.39, for a total transaction of $632,616.00.
  • On Thursday, November 14th, Metin Kurtoglu sold 25,900 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.44, for a total transaction of $425,796.00.

Cartesian Therapeutics Stock Down 2.7 %

RNAC traded down $0.47 during trading on Tuesday, reaching $17.16. The stock had a trading volume of 105,686 shares, compared to its average volume of 132,021. Cartesian Therapeutics, Inc. has a 1-year low of $11.66 and a 1-year high of $41.87. The firm has a market capitalization of $436.12 million, a price-to-earnings ratio of -0.32 and a beta of 0.56. The stock has a 50 day moving average of $19.32 and a two-hundred day moving average of $18.19.

Analysts Set New Price Targets

RNAC has been the topic of a number of research reports. Cantor Fitzgerald upgraded Cartesian Therapeutics to a “hold” rating in a research report on Monday, December 2nd. Needham & Company LLC reissued a “buy” rating and set a $41.00 price target on shares of Cartesian Therapeutics in a report on Tuesday, December 3rd. HC Wainwright restated a “buy” rating and set a $45.00 price target (up previously from $41.00) on shares of Cartesian Therapeutics in a research report on Wednesday, December 4th. Finally, BTIG Research assumed coverage on shares of Cartesian Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.86.

View Our Latest Stock Report on Cartesian Therapeutics

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RNAC. BNP Paribas Financial Markets grew its stake in shares of Cartesian Therapeutics by 122.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company’s stock worth $27,000 after purchasing an additional 909 shares during the last quarter. Point72 DIFC Ltd bought a new position in shares of Cartesian Therapeutics in the second quarter valued at $47,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Cartesian Therapeutics in the second quarter valued at $49,000. Barclays PLC boosted its stake in shares of Cartesian Therapeutics by 208.6% during the 3rd quarter. Barclays PLC now owns 11,611 shares of the company’s stock worth $188,000 after acquiring an additional 7,849 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Cartesian Therapeutics during the 2nd quarter worth $351,000. 86.95% of the stock is owned by institutional investors and hedge funds.

Cartesian Therapeutics Company Profile

(Get Free Report)

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

Read More

Insider Buying and Selling by Quarter for Cartesian Therapeutics (NASDAQ:RNAC)

Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.